In obese mice, a compound called G49 reduces weight and improves metabolism only when both glucagon and GLP-1 receptors are active; blocking either receptor significantly reduces weight loss and...

In obese mice, the drug G49 reduces weight and activates fat-burning tissue only when both the glucagon and GLP-1 receptors are active. Blocking either one reduces its effect, but blocking both stops it entirely.

In obese mice, a drug called G49 boosts calorie burning and activates fat tissue that generates heat, but this effect only occurs if the protein UCP1 is present; without UCP1, the drug fails to reduce weight or increase heat production, even though other metabolic signals remain unchanged.

In obese mice, a single injection of a specific drug causes fat cells to break down stored fat, releasing fatty acids into the blood. This triggers a series of metabolic changes in the liver and increases a hormone that activates heat-producing fat tissue, resulting in weight loss over seven days.

In obese mice, a compound called G49 triggers fat breakdown in white fat tissue through the glucagon receptor, which leads to the release of two signaling molecules—FGF21 and adiponectin—from the liver. These molecules activate brown fat, increasing energy expenditure and reducing body weight.

In obese mice, a single injection of a specific drug called G49 causes fat cells to break down stored fat quickly, releasing a large increase of free fatty acids into the blood. This process depends on the glucagon receptor and happens before changes occur in the liver and brown fat.